Patient 006 in cohort 2 had EGFR-amplified glioblastoma having progressed on 2 prior therapies of standard chemoradiation followed by 11 cycles of adjuvant temozolomide and 1 cycle of an investigational proteasome inhibitor on a clinical trial. The gene discussed is EGFR; the disease is glioblastoma.